Skip to content

A Method for in-vivo Gene Therapy to Cure SCD without Myeloablative Toxicity

This technology uses in vivo gene editing to directly and quantitatively control the expression of KLF1

Published: 8th March 2022
A Method for in-vivo Gene Therapy to Cure SCD without Myeloablative Toxicity
Source: Kateryna_Kon,https://stock.adobe.com/uk/108041889, stock.adobe.com
IP Status
  • Provisional patent